肺腺癌化疗疗效相关血浆差异蛋白质组学研究
Identification of differential plasma proteins in lung adnocarcinoma treated with chemotherapy
朱敬华 1王晓华 1王富强1
作者信息
- 1. 210009 江苏 南京,江苏省肿瘤医院肿瘤内科
- 折叠
摘要
目的 分析晚期肺腺癌患者培美曲塞联合顺铂方案化疗进展组和非进展组的血浆差异蛋白质组,筛选肺腺癌化疗疗效相关的分子标志物.方法 将4例进展组和4例非进展组治疗前和治疗后的血浆分别进行二维电泳,凝胶蛋白图谱寻找差异蛋白质点,结合基质辅助激光解吸电离飞行时间质谱鉴定差异蛋白质点.结果 建立了两组的二维凝胶电泳图谱,选取其中21个差异蛋白点进行分析,19个蛋白点鉴定成功,包括如丙酮酸激酶M2、腺苷酸激酶5、a-2抗纤维蛋白溶酶的前体,r纤维蛋白、氧化固醇结合蛋白相关蛋白3等.结论 肺腺癌不同化疗疗效患者的血浆差异蛋白可能为化疗疗效预测的生物标志物.
Abstract
Objective To seek out plasma protein markers for predicting chemotherapy sensitivity of ad-vanced lung adenocarcinoma patients who experienced pemetrexed combined cisplatin by screening plasma different expressed proteome in chemosensitive or resistant patients. Methods 8 patients were included. Plasma from the progression group and the non-progression group were collected before and after chemotherapy and analyzed using a proteomic approach with two-dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry ( MALDI-TOF-MS) . Results The 2-DE image of the two groups was set. 21 differ-ential protein spots were analyzed by MALDI-TOF-MS, and 19 protein spots were identified, including Pyruvate Ki-nase M2, Adenylate kinase 5, alpha-2-antiplasmin precursor, fibrinogen gamma, oxysterol binding protein-related protein 3, etc. Conclusion Differential protein in plasma could be used as biomarkers to predict chemotherapy sen-sitivity.
关键词
肺腺癌/化学治疗/肿瘤标志物/蛋白质组学Key words
lung adenocarcinoma/chemotherapy/tumor biomarkers/proteomics引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据